Osteoarticular TB specimen yield rates. Large joint analysis at a single centre.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

Conflict of interest statement: No conflict of interest or disclosures to be made by all authors. 17. Calcif Tissue Int. 2025 Feb 21;116(1):42. doi: 10.1007/s00223-025-01349-x. Long-Term Changes in Parameters of Bone Quality in Kidney Transplant Recipients Treated with Denosumab. Pollastri F(1), Fassio A(2), Ferraro PM(3), Andreola S(3), Gambaro G(3), Spasiano A(3), Caletti C(3), Stefani L(3), Gatti M(4), Fabbrini P(4), Rossini M(2), Galvagni I(2), Gatti D(2), Adami G(2), Viapiana O(2). Author information: (1)Rheumatology Unit, University of Verona, Policlinico GB Rossi, 37134, Verona, Italy. franpollastri@yahoo.it. (2)Rheumatology Unit, University of Verona, Policlinico GB Rossi, 37134, Verona, Italy. (3)Nephrology Unit, University of Verona, Verona, Italy. (4)Department of Nephrology and Dialysis, Ospedale Bassini, ASST Nord Milano-Cinisello Balsamo, Milan, Italy. Kidney transplant recipients (KTRs) have an elevated fracture risk. While dual-energy X-ray absorptiometry (DXA) is commonly used to assess areal bone mineral density (aBMD), it does not capture all aspects of bone quality. We investigated the long-term effects on bone DXA-derived indices of bone quality in KTRs treated with denosumab and untreated with denosumab. This is a retrospective study, including KTRs treated with denosumab and untreated age and sex-matched KTR controls. DXA-derived parameters, including trabecular bone score (TBS) and 3D-DXA parameters, were measured at the lumbar spine and femur at baseline and after four years. Hierarchical linear models were used to assess the between-group effect of treatment over time, also adjusting for site-specific aBMDs. We enrolled 23 KTRs treated with denosumab and 23 KTR denosumab-untreated KTRs. Significant between-group differences over time in favor of the denosumab group were observed for TBS (0.843, 95%CI 0.439; 1.248,p